Secondary outcomes

[키워드] 1:1 Acute coronary syndrome acute respiratory distress acute respiratory distress syndrome Adverse Adverse drug reaction Agastya Agastya Haritaki alcoholism ARDS Arm arrhythmia Ashwagandha Atrial fibrillation Ayurveda baseline biochemical blinded Blinding calculated Care CBC change chronic respiratory disease clinical clinical assessment Clinical Management Protocol comparator completion Computed tomography conducted confidence confidence level coronary syndrome COVID 19 COVID-19 COVID-19 case Critically ill Critically ill patient critically ill patients CTRI D-dimer depressive diabetes Diabetes Mellitus diagnosed Diego disease dropout rate drug drug reaction Effect Efficacy element eligible enrolled enrolment evening excluded exploratory study generate GMP Government Government of India group hematological hepatic disease HIV HRCT hs-CRP hypersensitivity IgM antibodies IgM antibody illness illnesses immunosuppressive medications Impact impaired cognition index India intensive care intensive care unit Intervention invasive respiratory support journal Laboratory parameters lactating women Level life long term long-COVID malignancy management motor neuron motor neuron disease multiple sclerosis Myocardial infarction negative RT-PCR number objective Open-label open-label design outcome parallel group parameter participant Participants past history Patient Pharmaceutical Company Pittsburgh positive RT-PCR Post-COVID pregnant Previous studies protocol provided pulmonary Pulmonary function test pulmonary tuberculosis Quality Quality of life random randomised randomised controlled trial Randomized Randomized controlled trial recruitment Registered registry rehabilitation renal renal disease respiratory Respiratory disease respiratory distress Respiratory function Safety Sample Sample size SARS CoV SARS CoV-2 SARS-CoV-2 scale Science score secondary Secondary outcomes Sex Shortness of breath Sleep sleep quality SPSS Standard deviation status stroke study duration study group study period Study protocol Subjective substance dependence supplementary material syndrome Tablet the study group timeline Trial Trial registration Tuberculosis Version warm water water website WHO yoga
[DOI] 10.1186/s13063-021-05326-1 PMC 바로가기 [Article Type] Letter